Compare

Profound Medical Corp. vs Biotricity Inc. vs Vivos Therapeutics, Inc. vs Nephros Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearProfound Medical Corp.
PROF
Biotricity Inc.
BTCY
Vivos Therapeutics, Inc.
VVOS
Nephros Inc
NEPH
Year ended2025-12-312026-03-312025-12-312025-12-31
Revenue$16.10M$16.00M$17.44M$18.79M
Revenue growth (YoY)+50.7%+16.0%+16.0%+32.7%
Gross margin70.8%80.9%60.4%61.9%
Operating margin-256.3%10.6%-114.1%6.1%
Net margin-264.4%-15.0%-121.4%6.4%
Net income-$42.57M-$2.40M-$21.17M$1.19M
EPS (Diluted)$1.41-$0.12-$2.07$0.11
Operating cash flow-$38.21M-$719.0K-$15.26M$1.60M
Free cash flow-$38.38Mn/a-$17.60Mn/a
Cash & equivalents$59.72M$149.8K$2.03M$5.40M
Total assets$77.47M$6.45M$25.15M$13.64M
Total liabilities$11.04M$39.41M$26.70M$3.44M
Shareholders' equity$66.43M-$34.68M-$1.49M$10.20M
Return on year-end equity-64.1%n/an/a11.7%
Shares outstanding36.29M28.60M9.29M10.64M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearProfound Medical Corp.Biotricity Inc.Vivos Therapeutics, Inc.Nephros Inc
Latest$16.10M
Ended 2025-12-31
$16.00M
Ended 2026-03-31
$17.44M
Ended 2025-12-31
$18.79M
Ended 2025-12-31
1 year earlier$10.68M
Ended 2024-12-31
$13.79M
Ended 2025-03-31
$15.03M
Ended 2024-12-31
$14.16M
Ended 2024-12-31
2 years earlier$7.20M
Ended 2023-12-31
$12.06M
Ended 2024-03-31
$13.80M
Ended 2023-12-31
$14.24M
Ended 2023-12-31
3 years earliern/a$9.64M
Ended 2023-03-31
$16.02M
Ended 2022-12-31
$9.97M
Ended 2022-12-31
4 years earliern/a$7.65M
Ended 2022-03-31
$16.89M
Ended 2021-12-31
$10.22M
Ended 2021-12-31